Published in Nat Rev Nephrol on July 01, 2009
Cancer in the transplant recipient. Cold Spring Harb Perspect Med (2013) 1.06
A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation (2015) 0.83
Transition from cyclosporine-induced renal dysfunction to nephrotoxicity in an in vivo rat model. Int J Mol Sci (2014) 0.78
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation (2009) 2.33
Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation (2004) 1.82
mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) (2008) 1.22
Malignancy in kidney transplant recipients. Drugs (2008) 1.08
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol (2005) 1.06
Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol (2005) 1.04
Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation (2006) 1.02
Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation (2009) 3.43
Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation (2008) 3.43
Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant (2003) 2.21
Associations of pretransplant weight and muscle mass with mortality in renal transplant recipients. Clin J Am Soc Nephrol (2011) 1.90
Age and the associations of living donor and expanded criteria donor kidneys with kidney transplant outcomes. Am J Kidney Dis (2012) 1.81
Health insurance considerations for adolescent transplant recipients as they transition to adulthood. Pediatr Transplant (2007) 1.68
Living donor kidney versus simultaneous pancreas-kidney transplant in type I diabetics: an analysis of the OPTN/UNOS database. Clin J Am Soc Nephrol (2009) 1.66
Transplant tourism in the United States: a single-center experience. Clin J Am Soc Nephrol (2008) 1.65
Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis (2010) 1.65
Outcomes of simultaneous pancreas-kidney transplantation in type 2 diabetic recipients. Clin J Am Soc Nephrol (2011) 1.49
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int (2011) 1.37
Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database. Transplantation (2012) 1.31
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation (2010) 1.28
Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant (2005) 1.28
Outcomes of kidney transplantation from older living donors to older recipients. Am J Kidney Dis (2008) 1.25
Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation (2010) 1.23
Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant (2005) 1.22
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation (2011) 1.12
Patient and graft outcomes from deceased kidney donors age 70 years and older: an analysis of the Organ Procurement Transplant Network/United Network of Organ Sharing database. Transplantation (2008) 1.10
Higher recipient body mass index is associated with post-transplant delayed kidney graft function. Kidney Int (2011) 1.10
Novel strategies in immunosuppression: issues in perspective. Transplantation (2011) 1.09
An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation (2010) 1.08
Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation (2006) 1.07
Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant (2005) 1.06
Timing of dialysis initiation in transplant-naive and failed transplant patients. Nat Rev Nephrol (2012) 1.04
Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant (2003) 1.03
Pancreas after living donor kidney versus simultaneous pancreas-kidney transplant: an analysis of the organ procurement transplant network/united network of organ sharing database. Transplantation (2010) 1.03
Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation (2013) 1.03
Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation (2004) 1.02
Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation (2005) 1.02
Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol (2010) 1.01
Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant (2005) 1.01
A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant (2005) 1.00
Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation (2010) 0.99
Outcomes of dual adult kidney transplants in the United States: an analysis of the OPTN/UNOS database. Transplantation (2008) 0.99
Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol (2006) 0.99
Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int (2008) 0.98
Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation (2009) 0.98
Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albumin. J Am Soc Nephrol (2007) 0.97
Alemtuzumab induction in deceased donor kidney transplantation. Transplantation (2007) 0.97
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation (2010) 0.97
Belatacept. Nat Rev Drug Discov (2011) 0.96
Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant (2004) 0.96
Management of mineral and bone disorder after kidney transplantation. Curr Opin Nephrol Hypertens (2012) 0.95
The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. Transplantation (2009) 0.95
Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transpl Int (2012) 0.93
Immunosuppression of the elderly kidney transplant recipient. Transplantation (2007) 0.93
Risk factors for development of new-onset diabetes mellitus in adult heart transplant recipients. Transplantation (2010) 0.93
Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation (2012) 0.92
Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation (2006) 0.92
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med (2016) 0.92
Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database. Transplantation (2006) 0.92
Analysis of the United Network for Organ Sharing database comparing renal allografts and patient survival in combined liver-kidney transplantation with the contralateral allografts in kidney alone or kidney-pancreas transplantation. Transplantation (2003) 0.91
Targeting JAK3 in kidney transplantation: current status and future options. Curr Opin Organ Transplant (2011) 0.88
Kinetics of hepatitis C virus load during hemodialysis: novel perspectives. J Nephrol (2003) 0.88
Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol (2011) 0.86
Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation (2008) 0.86
Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation (2005) 0.86
Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. Clin J Am Soc Nephrol (2011) 0.85
CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. Transplantation (2003) 0.85
Kidney transplantation: the ideal immunosuppression regimen. Adv Chronic Kidney Dis (2009) 0.85
Allocating deceased donor kidneys: maximizing years of life. Am J Kidney Dis (2007) 0.84
Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. Clin J Am Soc Nephrol (2011) 0.84
Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int (2012) 0.84
Dialysis modality and outcomes in kidney transplant recipients. Clin J Am Soc Nephrol (2011) 0.84
Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. Clin Transplant (2010) 0.83
HBV infection in patients with end-stage renal disease. Semin Liver Dis (2004) 0.83
How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept. Curr Opin Organ Transplant (2010) 0.83
Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update. Biologics (2012) 0.83
Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of United network of organ sharing database between 1994 and 1999. Transplantation (2002) 0.83
Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation (2004) 0.83
Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation. Transplantation (2009) 0.83
Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence. Am J Transplant (2002) 0.83
Isolated heart and liver transplant recipients are at low risk for polyomavirus BKV nephropathy. Clin Transplant (2006) 0.82
Immunosuppression in renal transplantation: some aspects for the modern era. Transplant Rev (Orlando) (2008) 0.82
Obesity was associated with inferior outcomes in simultaneous pancreas kidney transplant. Transplantation (2010) 0.82
Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation (2012) 0.82
Native renal function after combined liver-kidney transplant for type 1 hepatorenal syndrome: initial report on the use of postoperative Technetium-99 m-mercaptoacetyltriglycine scans. Transpl Int (2013) 0.81
Novel immunosuppression: small molecules and biologics. Semin Nephrol (2007) 0.81
Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet (2009) 0.81
Donor biopsy and kidney transplant outcomes: an analysis using the Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) database. Transplantation (2007) 0.81
Alemtuzumab induction in kidney transplantation. Clin Transpl (2005) 0.81
Fabry disease in a renal allograft. Am J Transplant (2003) 0.81
Association of pre-transplant erythropoiesis-stimulating agent responsiveness with post-transplant outcomes. Nephrol Dial Transplant (2012) 0.81
Kidney transplant outcomes in patients with Fabry disease. Transplantation (2009) 0.80
Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol (2007) 0.80
Transplantation with pancreas after living donor kidney vs. living donor kidney alone in type 1 diabetes mellitus recipients. Clin Transplant (2010) 0.80
Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. Transplantation (2009) 0.80
BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant (2004) 0.80
Risk factors for development of new-onset diabetes mellitus in pediatric renal transplant recipients: an analysis of the OPTN/UNOS database. Transplantation (2010) 0.80
Evolving trends in induction therapy. Transplant Rev (Orlando) (2009) 0.80
Belatacept in kidney transplantation. Curr Opin Organ Transplant (2012) 0.80
Outcomes of renal transplantation in recipients with Wegener's granulomatosis. Clin Transplant (2010) 0.80
Cause of death with graft function among renal transplant recipients in an integrated healthcare system. Transplantation (2011) 0.79
A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation (2016) 0.79
Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol Dial Transplant (2012) 0.79
Intermediate-term outcomes associated with kidney transplantation in recipients 80 years and older: an analysis of the OPTN/UNOS database. Transplantation (2010) 0.79
Improved survival among sickle cell kidney transplant recipients in the recent era. Nephrol Dial Transplant (2013) 0.79
Sirolimus: defining nephrotoxicity in the renal transplant recipient. Clin J Am Soc Nephrol (2007) 0.78